Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PRECISION BIOSCIENCES INC Director's Dealing 2019

Mar 27, 2019

34491_dirs_2019-03-27_2b9ed5f1-2459-40d2-bd73-02b268309ef8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27

Reporting Person: Schinazi Raymond F (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series B Preferred Stock $ Common Stock (56102) Indirect

Footnotes

F1: Each share of Series B Preferred Stock is convertible at the holder's election into approximately 0.468452971537734 share of the common stock of Precision BioSciences, Inc. (the "Issuer") (on an adjusted basis, after giving effect to the 1-for-2.134686 reverse stock split effected by the Issuer in connection with its initial public offering) and has no expiration date. The Series B Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are held of record by RFS Partners, LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.